Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Endometrial Cancer Recurrent 1Breast Neoplasms 1Advanced Cancers 1Adenocarcinoma of Lung 1ALK or ROS1-positive NSCLC 1

Interventions

TIC10 compound 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endometrial Cancer Recurrent × Crizotinib × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡